

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10519897
Filing Date	2004-12-31
First Named Inventor	Ingemar Starke
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	133087.07001

U.S.PATENTS						<input type="button" value="Remove"/>
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5756470		1998-05-26	Yumibe et al.	
	2	5919672		1999-07-06	Homann et al.	
	3	RE37721		2002-05-28	Rosenblum et al.	
	4	5633246		1997-05-27	McKittrick et al.	
	5	5744467		1998-04-28	McKittrick et al.	
	6	5661145		1997-08-26	Davis	

If you wish to add additional U.S. Patent citation information please click the Add button.

**U.S.PATENT APPLICATION PUBLICATIONS**

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear

/Mark Berch/ (07/22/2008)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10519897
Filing Date	2004-12-31
First Named Inventor	Ingemar Starke
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	133087.07001

1	20020137690	2002-09-26	Ghosal et al.	
2	20030119757	2003-06-26	Schering Corp.	
3	20030119428	2003-06-26	Schering Corp.	
4	20040018060	2003-06-26	Schering Corp.	
5	20040018061	2004-01-29	Jansson	
6	20040254369	2004-12-16	Patel	
7	20050096307	2005-05-05	Schering Corp.	
8	20050267049	2005-12-01	Goulet et al.	
9	20060046996	2006-03-02	Nissan Chemical Ind Ltd.	
10	20060069080	2006-06-29	Incyte Corp.	
11	20070078098	2007-04-05	Merck and Co., Inc.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/  
/Mark Berch/ (07/22/2008)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10519897
Filing Date	2004-12-31
First Named Inventor	Ingemar Starke
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	133087.07001

12	20070129540		2007-06-07	Opus Organics Pvt Ltd.	
13	20070049748		2007-03-01	Dr Reddys Lab Ltd Dr	
14	20080064676		2008-03-13	AstraZeneca AB	
15	20070142304		2007-06-21	AstraZeneca AB	

If you wish to add additional U.S. Published Application citation information please click the Add button

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T5
1	2004005247		WO		2004-01-15	AstraZeneca UK Ltd.		<input type="checkbox"/>
2	2004081002		WO		2004-09-23	Schering Corporation		<input type="checkbox"/>
3	9508532		WO		1995-03-30	Schering Corporation		<input type="checkbox"/>
4	9302048		WO		1993-02-04	Schering Corporation		<input type="checkbox"/>
5	9417038		WO		1994-08-04	Schering Corporation		<input type="checkbox"/>

/Mark Berch/ (07/22/2008)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10519897
Filing Date	2004-12-31
First Named Inventor	Ingemar Starke
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	133087.07001

6	9526334	WO		1995-10-05	Schering Corporation		<input type="checkbox"/>
7	9616037	WO		1996-05-30	Schering Corporation		<input type="checkbox"/>
8	9535277	WO		1995-12-28	Schering Corporation		<input type="checkbox"/>
9	0250090	WO		2002-06-27	Schering Corporation		<input type="checkbox"/>
10	9619450	WO		1996-06-27	Schering Corporation		<input type="checkbox"/>
11	9716455	WO		1997-05-09	Schering Corporation		<input type="checkbox"/>
12	9716424	WO		1997-05-09	Schering Corporation		<input type="checkbox"/>
13	03088962	WO		2003-10-30	Merck & Co., Inc.		<input type="checkbox"/>
14	2004000803	WO		2003-12-31	Aventis Pharma Deutschland		<input type="checkbox"/>
15	2004000804	WO		2003-12-31	Aventis Pharma Deutschland		<input type="checkbox"/>
16	2004000805	WO		2003-12-31	Aventis Pharma Deutschland		<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

/Mark Berch/ (07/22/2008)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10519897
Filing Date	2004-12-31
First Named Inventor	Ingemar Starke
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	133087.07001

17	2004010993	WO		2004-02-05	Merck Sharp & Dohme Limited		<input type="checkbox"/>
18	2004010948	WO		2004-02-05	Karykion Inc.		<input type="checkbox"/>
19	2004014947	WO		2004-02-19	Aventis Pharma Deutschland		<input type="checkbox"/>
20	2005061452	WO		2005-07-07	AstraZeneca AB		<input type="checkbox"/>
21	2005062824	WO		2005-07-14	Merck & Co. Inc.		<input type="checkbox"/>
22	2006017257	WO		2006-02-16	Phenomix Corp.		<input type="checkbox"/>
23	2005061451	WO		2005-07-07	AstraZeneca AB		<input type="checkbox"/>
24	2005062897	WO		2005-07-14	Dr Reddys Lab Ltd Dr		<input type="checkbox"/>
25	2005066120	WO		2005-07-21	Ranbaxy Lab Ltd.		<input type="checkbox"/>
26	2005069900	WO		2005-08-04	Merck & Co. Inc.		<input type="checkbox"/>
27	03026643	WO		2003-04-03	Schering Corp.		<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

/Mark Berch/ (07/22/2008)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10519897
Filing Date	2004-12-31
First Named Inventor	Ingemar Starke
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	133087.07001

	28	04043456	WO		2004-05-27	Schering Corp.		<input type="checkbox"/>
	29	04043457	WO		2004-05-27	Schering Corp.		<input type="checkbox"/>
	30	2005113495	WO		2005-12-01	Aventis Pharma GMBH		<input type="checkbox"/>
	31	04099132	WO		2004-11-18	Ranbaxy Laboratories Limited		<input type="checkbox"/>
	32	04107958	WO		2004-12-16	Schering Corp.		<input type="checkbox"/>
	33	05000353	WO		2005-01-06	Kotobuki Pharmaceutical Co. Ltd.		<input type="checkbox"/>
	34	2005021495	WO		2005-03-10	Microbia Inc.		<input type="checkbox"/>
	35	2007075702	WO		2007-07-05	Schering Corporation		<input type="checkbox"/>
	36	2005033100	WO		2005-04-14	Lipideon Biotechnology AG		<input type="checkbox"/>
	37	2005067903	WO		2005-07-25	Panacea Boitec Ltd.		<input type="checkbox"/>
	38	05042692	WO		2005-05-12	Forbes Medi Tech Inc.		<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

/Mark Berch/ (07/22/2008)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10519897
Filing Date	2004-12-31
First Named Inventor	Ingemar Starke
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	133087.07001

	39	2005113496	WO		2005-12-01	Aventis Pharma GMBH	<input type="checkbox"/>
	40	2005044256	WO		2005-05-19	Merck & Co. Inc.	<input type="checkbox"/>
	41	2005049592	WO		2005-06-02	Hetero Drugs Ltd.	<input type="checkbox"/>
	42	2005047248	WO		2005-05-26	Microbia Inc.	<input type="checkbox"/>
	43	2005058316	WO		2005-06-30	Sumitomo Pharma	<input type="checkbox"/>
	44	1362855	EP		2003-11-19	Kotobuki Pharmaceutical Co. Ltd.	<input type="checkbox"/>
	45	1413331	EP		2001-09-21	Schering Corporation	<input type="checkbox"/>
	46	2007008529	WO		2007-01-18	Kalypsys, Inc.	<input type="checkbox"/>
	47	2007008541	WO		2007-01-18	Kalypsys, Inc.	<input type="checkbox"/>
	48	2007030721	WO		2007-03-15	Teva Pharmaceutical Industries Ltd. et al.	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

**NON-PATENT LITERATURE DOCUMENTS**

Remove

/Mark Berch/ (07/22/2008)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Not for submission under 37 CFR 1.99)

Application Number	10519897
Filing Date	2004-12-31
First Named Inventor	Ingemar Starke
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	133087.07001

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	McKittrick et al., "Synthesis of C3 heteroatom-substituted azetidinones that display potent cholesterol absorption inhibitory activity," <i>J. Med. Chem.</i> (1998) 41(5):752-759.	<input type="checkbox"/>
	2	Kvaerno et al., "Synthesis and in vitro evaluation of inhibitors of intestinal cholesterol absorption," <i>J. Med. Chem.</i> (2005) 48(19):6035-6053.	<input type="checkbox"/>
	3	Burnett "Beta-lactam cholesterol absorption inhibitors," <i>Curr. Med. Chem.</i> (2004) 11:1873-1887.	<input type="checkbox"/>
	4	Seedorf et al., "Cholesterol absorption inhibitor ezetimibe blocks uptake of oxidized LDL in human macrophages," <i>Biochem Biophys Research Commun.</i> (2004) 320(4):1337-1341.	<input type="checkbox"/>
	5	Kvaerno et al., "An in vitro assay for evaluation of small-molecule inhibitors of cholesterol absorption," (2004) 43 (35):4653-4656.	<input type="checkbox"/>
	6	Clader "Ezetimibe and other azetidinone cholesterol absorption inhibitors," <i>Curr Topics in Med Chem.</i> (2005) 5 (3):243-256.	<input type="checkbox"/>
	7	Garcia-Calvo et al., "The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)," <i>PNAS</i> (2005) 102(23):8132-8137.	<input type="checkbox"/>
	8	Ritter et al., "Heterocyclic ring scaffolds as small-molecule cholesterol absorption inhibitors," <i>Org. Biomol. Chem.</i> (2005) 3:3514-3523.	<input type="checkbox"/>
	9	Dugar et al., "Gamma-lactams and related compounds as cholesterol absorption inhibitors homologs of the beta-lactam cholesterol absorption inhibitor SCH 48461," <i>Bioorganic &amp; Medicinal Letters</i> (1995) 5(24):2947-2952.	<input type="checkbox"/>
	10	Mounsey et al., "Diet may slow progression of diabetic nephropathy," <i>The Journal of Family Practice</i> (2003) 52 (9):672-673.	<input type="checkbox"/>

/Mark Berch/ (07/22/2008)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Not for submission under 37 CFR 1.99)

Application Number	10519897
Filing Date	2004-12-31
First Named Inventor	Ingemar Starke
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	133087.07001

11	Sobieszczyk et al., "Acute pulmonary embolism: don't ignore the platelet," Circulation (2002) 106(14):1748-1749.	<input type="checkbox"/>
12	Notice of Copending applications (2pp.)	<input type="checkbox"/>
13	Journal of the American College of Cardiology (2000) 35(1):252A.	<input type="checkbox"/>
14	van Heek et al., "Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663," Br. J. Pharmacol (2000) 129(8):1748-1754.	<input type="checkbox"/>
15	Yang et al., "Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de Pointes," Circulation (2002) 105(16):1943-1948.	<input type="checkbox"/>
16	Zaks et al., "Enzymatic glucuronidation of a novel cholesterol absorption inhibitor, Sch 58235, Appl Biochem Biotechnol. (1998) 73(2-3):205-214.	<input type="checkbox"/>
17	Clader "The discovery of ezetimibe: a view from outside the receptor," J Med Chem (2004) 47(1):1-9.	<input type="checkbox"/>
18	Altmann et al., "Niemann-pick C1 like 1 protein is critical for intestinal cholesterol absorption," Science (2004) 303:1201-1204.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	/Mark Berch/ (07/22/2008)	Date Considered
--------------------	---------------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/